The senior members of our research team have more than twenty year R&D and management experience individually in multinational pharmaceutical companies, and with expertise in all major disciplines for drug discovery and development.
Our advisors include well-known Chinese Key Opinion Leaders in Genito-urinary oncology and urology, as well as experts in pharmacological research, clinical development and regulatory affairs.
We are one of the leading companies in applying the unique strategy of “Through validation of a new MoA of an old drug to effectively reposition and develop follow-on new products”.
Proven Track Record:
Our clinical lead APL-1202 was in-licensed a patented technology from Johns Hopkins University. We have also established successful collaborations with Okayama University in Japan, Chinese Academy of Medical Sciences Institute of Medicine, and the Chinese Academy of Military Medical Sciences.